Milton Boyer - Albany Molecular Senior Vice President - Drug Product Manufacturing
President
Mr. Milton Boyer is Senior Vice President Drug Product Manufacturing of the Company. He was Vice President of Parenterals. Mr. Boyer expertise from OsoBio will be applied across all phases of Drug Product, which spans from PreFormulation and Formulation Development all the way through to Late Phase and Commercial Parenteral Manufacturing. since 2015.
| Tenure | 9 years |
| Phone | 518 512-2000 |
| Web | www.amriglobal.com |
Albany Molecular Management Efficiency
The company has return on total asset (ROA) of (0.0657) % which means that it has lost $0.0657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.1137) %, meaning that it created substantial loss on money invested by shareholders. Albany Molecular's management efficiency ratios could be used to measure how well Albany Molecular manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 647.96 M in liabilities with Debt to Equity (D/E) ratio of 204.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Albany Molecular Research has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Albany Molecular until it has trouble settling it off, either with new capital or with free cash flow. So, Albany Molecular's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albany Molecular Research sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albany to invest in growth at high rates of return. When we think about Albany Molecular's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | PRESIDENT Age | ||
| Anthony McDuffie | Boyd Gaming | 59 | |
| Gerard Versteegh | SunOpta | 54 | |
| Lillian Barlett | SunOpta | 53 | |
| Brian Larson | Boyd Gaming | 62 | |
| Craig Abrahams | Playtika Holding Corp | 47 | |
| Theodore Bogich | Boyd Gaming | 68 | |
| Marianne Johnson | Boyd Gaming | 66 | |
| Josh Hirsberg | Boyd Gaming | 62 | |
| Steve Thompson | Boyd Gaming | 55 | |
| James Gratzek | SunOpta | 51 | |
| Stephen Thompson | Boyd Gaming | 64 | |
| Ted Bogich | Boyd Gaming | N/A | |
| Jill Barnett | SunOpta | 50 | |
Management Performance
| Return On Equity | -22.11 | |||
| Return On Asset | -0.0657 |
Albany Molecular Research Leadership Team
Elected by the shareholders, the Albany Molecular's board of directors comprises two types of representatives: Albany Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Albany. The board's role is to monitor Albany Molecular's management team and ensure that shareholders' interests are well served. Albany Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Albany Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Svokos, COO | ||
| Arthur Roth, Independent Director | ||
| Gerardo Gutierrez, Director | ||
| Thomas Ambra, Non-Executive Chairman of the Board | ||
| Lori Henderson, Vice President General Counsel, Secretary | ||
| Milton Boyer, Senior Vice President - Drug Product Manufacturing | ||
| Anthony Maddaluna, Director | ||
| Kenneth Hagen, Director | ||
| Fernando Napolitano, Director | ||
| Una Ryan, Lead Independent Director | ||
| David Deming, Director | ||
| Kevin Connor, Independent Director | ||
| Jimmy Wang, CIO | ||
| Gabriel Leung, Independent Director | ||
| Steven Hagen, Sr. VP of Manufacturing, Pharmaceuticals and Operations | ||
| Christopher Conway, Senior Vice President - Global Sales and Marketing | ||
| Felicia Ladin, CFO, Senior Vice President Treasurer | ||
| Veronica Jordan, Independent Director | ||
| William Marth, CEO and President and Director |
Albany Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Albany Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.11 | |||
| Return On Asset | -0.0657 | |||
| Profit Margin | (11.94) % | |||
| Operating Margin | 0.87 % | |||
| Current Valuation | 981.79 M | |||
| Shares Outstanding | 42.7 M | |||
| Shares Owned By Insiders | 15.91 % | |||
| Shares Owned By Institutions | 97.30 % | |||
| Number Of Shares Shorted | 5.61 M | |||
| Price To Earning | (15.32) X |
Pair Trading with Albany Molecular
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albany Molecular position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albany Molecular will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Mastercard could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mastercard when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mastercard - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mastercard to buy it.
The correlation of Mastercard is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mastercard moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mastercard moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mastercard can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Albany Stock
If you are still planning to invest in Albany Molecular Research check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albany Molecular's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |